Lansoprazole

Generic Name
Lansoprazole
Brand Names
Prevacid, Prevpac
Drug Type
Small Molecule
Chemical Formula
C16H14F3N3O2S
CAS Number
103577-45-3
Unique Ingredient Identifier
0K5C5T2QPG
Background

Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...

Indication

Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...

Associated Conditions
Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer

Phase 3
Completed
Conditions
Duodenal Ulcer
Interventions
Drug: TAK-438
Drug: Lansoprazole
Drug: Placebo
First Posted Date
2011-10-17
Last Posted Date
2013-08-20
Lead Sponsor
Takeda
Target Recruit Count
372
Registration Number
NCT01452724

Bioequivalence Study of Lansoprazole DR Capsules 30 mg in Fasting Conditions

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Lansoprazole
First Posted Date
2011-01-05
Last Posted Date
2011-01-05
Lead Sponsor
Dr. Reddy's Laboratories Limited
Target Recruit Count
48
Registration Number
NCT01270308
Locations
🇮🇳

Bioserve Clinical Research (P) Ltd, Balanagar, Hyderabad, India

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Not Applicable
Completed
Conditions
Neuroendocrine Carcinoma (Carcinoid)
Interventions
Drug: lansoprazole
First Posted Date
2010-10-07
Last Posted Date
2013-01-16
Lead Sponsor
University of Western Ontario, Canada
Target Recruit Count
200
Registration Number
NCT01216267
Locations
🇨🇦

London Health Sciences Center and St. Joseph's Health Care, London, Ontario, Canada

PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers

Phase 4
Completed
Conditions
Peptic Ulcer
Interventions
Drug: Famotidine
Drug: Lansoprazole
First Posted Date
2010-08-12
Last Posted Date
2019-08-01
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
228
Registration Number
NCT01180179
Locations
🇨🇳

Endoscopy Center, Prince of Wales Hospital, Shatin, Hong Kong, China

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

First Posted Date
2010-08-04
Last Posted Date
2012-07-04
Lead Sponsor
Ascopharm Groupe Novasco
Target Recruit Count
82
Registration Number
NCT01175200
Locations
🇫🇷

Pitié Salpétrière Hospital, Paris, France

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

First Posted Date
2010-06-22
Last Posted Date
2011-06-28
Lead Sponsor
AstraZeneca
Target Recruit Count
149
Registration Number
NCT01147588
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

Safety and Efficacy of Lansoprazole in Patients With Reflux Disease

Phase 4
Completed
Conditions
Gastroesophageal Reflux
Interventions
Drug: Lansoprazole
First Posted Date
2010-06-02
Last Posted Date
2012-09-03
Lead Sponsor
Takeda
Target Recruit Count
506
Registration Number
NCT01135368

Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

Phase 3
Completed
Conditions
Helicobacter Pylori Infection
First Posted Date
2010-05-26
Last Posted Date
2011-08-09
Lead Sponsor
Deva Holding A.S.
Target Recruit Count
60
Registration Number
NCT01131026
Locations
🇹🇷

Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology, Kayseri, Turkey

Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)

First Posted Date
2010-05-14
Last Posted Date
2020-02-17
Lead Sponsor
Changhua Christian Hospital
Registration Number
NCT01123031

Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children

Phase 4
Completed
Conditions
Otitis Media With Effusion
Interventions
Drug: Placebo
Drug: Lansoprazole
First Posted Date
2010-03-05
Last Posted Date
2015-04-14
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
65
Registration Number
NCT01082029
Locations
🇨🇦

Mcmaster University Medical Centre 3V1 Clinic, Hamilton, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy